Prince Mario-Max Schaumburg-Lippe: Protein Hunters Target Alzheimer Disease Early

Proteins do the work of the body, and sometimes they fold the wrong way. When that happens early and quietly, disease can gain a head start of years. A new research team announced on October 27, 2026 wants to catch that first wrong fold – and Seattle company Nautilus Biotechnology will be doing much of the measuring.

Nautilus said it has joined SEEDS, a four-year, multi-center research consortium awarded up to $51.7 million by the Advanced Research Projects Agency for Health, known as ARPA-H. Nautilus expects to receive up to $6 million over the program to deploy its Voyager Platform. The name SEEDS is a mouthful worth spelling out once: Sequence-to-disease: Environment-aware Ensembles of Disordered proteins at Scale.

Why disordered proteins are such a promising target

Here is the science in plain terms. As many as half of human proteins may have intrinsically disordered regions – stretches whose shapes keep shifting instead of settling into one stable form. Most drugs are designed to fit stable shapes and binding pockets, so these shifting proteins have long been called undruggable. Hard to study. Easy to postpone.

SEEDS refuses to postpone them. The consortium aims to predict how disease-causing proteins misfold before irreversible damage occurs, then use those predictions to build new ways of detecting, slowing and treating neurodegenerative diseases and cancer. It sits inside ARPA-H’s BIOGAMI program, led by ARPA-H program manager Shannon Greene, which focuses on the earliest stages of protein dysfunction. Early is the whole strategy. Catch the change before the damage, and the medicine gets a fair fight.

The approach sits comfortably beside other early-action science readers met in personal mRNA therapy cutting melanoma return risk – different tools, same hopeful logic of intervening sooner and smarter.

What the Voyager Platform measures

Nautilus works on proteoforms – the distinct versions of a protein that drive its function. Two samples can hold the same protein on paper and behave quite differently in the body because the versions differ. Counting only the protein name is like counting families instead of people. You miss who is actually in the room.

The Voyager Platform uses a method called Iterative Mapping to analyze millions to billions of intact proteins, independently and at the same time. Its flow cells are designed to hold up to 10 billion intact protein molecules, and the method probes single molecules across tens to hundreds of cycles, recording a binding pattern for each one. Machine learning then turns those patterns into confident protein and proteoform counts. The instrument is built for a standard lab bench, with a guided touchscreen and no need for bespoke gas or fluidic connections – an unglamorous detail that decides whether a tool spreads or stays a showpiece.

Within SEEDS, Nautilus will study proteoforms of tau, a protein implicated in Alzheimer disease, and of EWS::FLI1, implicated in Ewing sarcoma, with work expected to extend to a larger set of disordered proteins. Samples will come from model systems, disease tissues and biofluids, starting with those two diseases. The data should then train AI models to predict how proteoforms push a protein toward aggregation, so researchers can design diagnostics and therapeutics from the predictions.

The people leading the work

SEEDS is co-led by the Buck Institute for Research on Aging and Georgetown University. Priyanka Joshi, assistant professor at Georgetown University School of Medicine and a SEEDS co-lead, explained the gap the team is filling: the field knows more about the downstream effects of protein misfolding than the upstream molecular causes. Iterative Mapping, she said, should help quantify the diverse proteoforms that may drive misfolding in the first place, in diseases where early intervention is critical.

Chuankai Zhou, principal investigator at the Buck Institute and the other co-lead, pointed to the practical payoff – Voyager data at high resolution could show how proteoforms contribute to distinct protein shapes, and how teams might preempt disease progression before irreversible damage occurs. Parag Mallick, Nautilus co-founder and chief scientist, said the team is excited to help define the link between proteoforms, misfolding and disease, and believes the data could unlock a new generation of proteoform-enabled diagnostics and therapeutics.

Work already underway

This is not a cold start, and that matters for a four-year clock. A Voyager field-evaluation unit at the Buck Institute has been generating tau proteoform data since early 2025. Nautilus opened an Iterative Mapping Early Access Program earlier this year, published validation of the method in the peer-reviewed journal Nature Methods, and is collaborating with the Michael J. Fox Foundation and Weill Cornell Medicine-Qatar on a proteoform assay for alpha-synuclein, the protein implicated in Parkinson disease. SEEDS is also the first use of Iterative Mapping in a pediatric cancer, Ewing sarcoma, and the company plans about 20 assays by mid-2028, ahead of a planned Voyager shipment in mid-2027.

Measurement science rarely gets applause, yet it quietly powers stories like sensors bringing top safety scores to everyday cars – better instruments, better decisions, sooner.

What success would look like

Picture a clinic visit five or ten years from now. A blood sample – a biofluid, in the language of the release – is screened for specific proteoform patterns. A pattern linked to early tau trouble shows up years before symptoms, while change is still slow and treatment has room to work. That is not a promise in the announcement, and no one at Nautilus or ARPA-H makes it. It is the direction of travel, stated carefully by people who measure things for a living.

The practical takeaway for families today is simpler. Research money is flowing toward earlier detection, the tools can now count single protein molecules by the billions, and a Seattle team will spend four years turning those counts into predictions doctors can use. For anyone who has watched a loved one face Alzheimer disease, earlier is not a small word. It is the whole hope – and SEEDS just put $51.7 million and some very good instruments behind it.

Also published on: